News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atox Bio Raises $3.25 Million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials


12/19/2011 7:23:02 AM

NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).

Read at BioSpace.com


comments powered by Disqus
Atox Bio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES